Navigation Links
Genelabs Technologies, Inc. Announces Resignation of President and CEO
Date:1/30/2008

Executive Chairman and CFO Assume Leadership Responsibilities; CEO Search

Underway

REDWOOD CITY, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that James A. D. Smith has resigned as President, Chief Executive Officer and Director of the company, effective January 29, 2008. Irene A. Chow, Ph.D., Executive Chairman of Genelabs' Board of Directors, and Frederick W. Driscoll, Genelabs' Chief Financial Officer, will assume leadership responsibilities until a successor is appointed.

Dr. Chow stated, "I want to thank Jim for his dedication and many years of service to the company. We wish him well in his future endeavors. The company has initiated an executive search for a CEO to lead it into the next phase of its development."

"Genelabs is well-positioned to execute on its internal development strategies and to support its collaboration partners -- Gilead, GlaxoSmithKline and Novartis. We are fully committed and confident about our ability to deliver on our business goal of translating research into novel antiviral therapeutics," stated Mr. Driscoll.

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program. We also have late-stage products for hepatitis E virus and lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit http://www.genelabs.com.

Note: Genelabs(R) and the Genelabs logo are registered trademarks of

Genelabs Technologies, Inc.

NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains forward-looking statements including statements regarding the Company's business strategy. These forward-looking statements are based on Genelabs' current expectations and are subject to uncertainties and risks, including failures or setbacks in our hepatitis C virus research and development programs or in our collaborations with Gilead, GlaxoSmithKline and Novartis. Please see the information appearing in Genelabs' filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, under the captions "Risk Factors" and "Forward-Looking Statements" for more discussion regarding these uncertainties and risks and others associated with the company's research programs, early stage of development and other risks which may affect the company or cause actual results to differ from those included in the forward-looking statements. Genelabs does not undertake any obligation to update these forward-looking statements or risks to reflect events or circumstances after the date of this release.

Contact: Frederick W. Driscoll

Chief Financial Officer

650-562-1424


'/>"/>
SOURCE Genelabs Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov
2. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
3. Healthcare Technologies, Ltd. Receives Notice From Nasdaq
4. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
5. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
6. ReBuilder Medical Technologies, Inc.s Recent Stock Price Volatility Explained
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
8. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
9. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
10. The PLSG Invests $115,000 in Innovention Technologies, LLC
11. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
(Date:12/8/2016)... 8, 2016 Savannah River Remediation LLC ... selected NewTechBio,s NT-MAX Lake & Pond Sludge ... bacteria, in conjunction with Hexa Armor/ Rhombo cover ... National Pollutant Discharge Elimination System requirements. ... steady history of elevated pH levels, above 8.5, ...
(Date:12/8/2016)... , Dec. 8, 2016   Biocept, ... leading commercial provider of clinically actionable liquid biopsy ... announces that clinical data featuring its Target Selector™ ... tissue biopsy for the detection of actionable biomarkers ... from research sponsored by Sara Cannon Research Institute ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. ... a Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based ... “The System Integrator Partner certification gives customers confidence that our engineers are fully ...
Breaking Biology Technology:
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/29/2016)... France , November 29, 2016 Nearly one ... Continue Reading ... ... is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: ...
(Date:11/22/2016)... , November 22, 2016 According to the ... IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), ... published by MarketsandMarkets, the market is expected to grow from USD 10.74 ... CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):